Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06739720 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Primary completion date changed from estimate of Jun 30, 2026 to Jan 15, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints revised (6)
    • Site details revised
    • Publications: details revised at 1 of 1 entry
    • Study title expanded, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation? The investigators will compare people taking the Lingzhi supplement to those who do not receive any treatment (waitlist group) to see if it works. Participants will: * Take 5 capsules once daily for 6 weeks (or wait to start treatment if in waitlist group) * Visit the clinic 2 times for blood tests (before and after taking the supplement) * Complete questionnaires 3 times about their fatigue and quality of life (4 times participants in the waitlist group)
Trial Details
NCT Number NCT06739720
Lead Sponsor The University of Hong Kong
Collaborators: Innovation and Technology Commission, Hong Kong
Conditions
(from sponsor)		 Chronic Fatigue Syndrome (CFS), Post-COVID ME/CFS
Related terms Fatigue Syndrome, Chronic
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov